Pharmazz, Inc.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Willowbrook IL United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2014
NCT02408731
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Chairman and CEO | Pharmazz, Inc. | Pharmazz India

Active Ingredients

Drugs in Phase 4 Trials (2)

centhaquine (5 trials)

sovateltide (7 trials)

Drugs in Phase 3 Trials (1)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (1)

centhaquin (Lyfaquin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Brain Ischemia (Phase 3)

Cerebral Infarction (Phase 3)

Hypovolemia (Phase 3)

Infarction (Phase 3)

Ischemia (Phase 3)

Shock (Phase 3)

Spinal Cord Injuries (Phase 2)

Stroke (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 4